---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-044387"
form_type: "8-K"
ticker: "MGRX"
cik: "0001938046"
company_name: "MANGOCEUTICALS, INC."
filed_at: "2023-12-11T23:59:59+00:00"
generated_at: "2026-06-07T15:14:22.297434+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Mangoceuticals enters licensing deal for Kyzatrex® testosterone capsules with Marius Pharmaceuticals

## Summary
- Issued 100,000 restricted shares to Marius for non-exclusive license to market Kyzatrex® on MangoRx telehealth platform.
- Two-year initial term; renews automatically if MangoRx maintains at least 2,500 monthly Kyzatrex patients.
- Marius can terminate without cause on 60 days' notice, or if 30% of patient milestone not met within 6 months of launch by Jan 31, 2024.
- MangoRx agrees not to market competing testosterone undecanoate products during term and 12 months after.

## SEC filing metadata
- accession: 0001493152-23-044387
- form_type: 8-K
- ticker: MGRX
- cik: 0001938046
- company_name: MANGOCEUTICALS, INC.
- filed_at: 2023-12-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1938046/000149315223044387/0001493152-23-044387-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1938046/000149315223044387/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-044387
- JSON: https://secwatch.observer/filing/0001493152-23-044387.json
- Plain text: https://secwatch.observer/filing/0001493152-23-044387.txt

## Key facts
- Material Agreements
  MANGOCEUTICALS, INC. entered into Marius Agreement with Marius Pharmaceuticals, LLC valued at 100,000 shares of our restricted common stock (effective 2023-12-10).
  - Action: entry
  - Agreement: license
  - Counterparty: Marius Pharmaceuticals, LLC
  - Value: 100,000 shares of our restricted common stock
  - Effective: 2023-12-10
  source text: On December 10, 2023, we entered into a Marketing Agreement with Marius Pharmaceuticals, LLC (“ Marius ”) allowing us the use of the trademark “Kyzatrex®” oral testosterone undecanoate softgel capsules
  evidence_url: https://www.sec.gov/Archives/edgar/data/1938046/000149315223044387/0001493152-23-044387-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.